Toxicity, Drug

3

Review clinical trials related to Toxicity, Drug. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia

A five-year prospective observational cohort study. The study is focused on observing the relation between static germline variants and therapeutic response in Indian children with acute lymphoblastic leukemia (ALL). The project is an International multicenter setup. This collaborative research project between Switzerland and India includes one main center in Geneva that has conceptualized, designed, received grants for the study and two investigating centers in India (Puducherry and New-Delhi) involved in study design, patient care and recruitment for this specific study. All the participants for the study will be recruited form these two centers in India, and no patient recruitment is planned at main center i.e. Geneva. The study will be conducted in two phases. The first aims to investigate genetic predisposition (static germline variants) to early chemotherapy treatment related toxicities (TRTs). The second aims to investigate somatic genetic markers associated with the efficacy of steroid treatment among patients undergoing the standardized IciCLe-ALL-14 treatment protocol. A total of 500 children with ALL will be recruited to investigate primary objective of the study i.e. TRT, and a subset of 250 patients will be included to investigate another research question i.e. response to steroid therapy.

Participants needed: 556
Trial details
Age: 1-18Biological sex: AllType: ObservationalSponsor: University of Geneva, SwitzerlandUpdated: Jan 15, 2026Locations: 2
Eligibility criteria

Age > 1 year old and ≤18 years old at enrolment [+5]

Previously tretaed patients [+2]

Status: Recruiting

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

Safe Stop IPI-NIVO Trial: Early discontinuation of nivolumab upon achieving a (confirmed) complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab

Participants needed: 80
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Erasmus Medical CenterUpdated: Feb 28, 2025Locations: 1
Eligibility criteria

18 years of age or older [+14]

Patients with SD/PD according to RECIST v1.1 [+7]